GlassScriptPhysician profile
Cierra Thompson
NPI 1871182725
$855.49
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.10 · 2022: $209 · 2023: $130 · 2024: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $214.79 | 2021-2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $179.81 | 2023-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $152.97 | 2022 | |
| Sanofi Pasteur INC. | $66.06 | 2022-2023 | |
| Vertical Pharmaceuticals, LLC | $43.71 | 2024 | Relexxii, Methylphenidate Hydrochloride |
| Corium, LLC | $42.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.74 | 2024 | |
| Sobi, INC | $24.26 | 2022 | |
| Seqirus USA INC | $21.80 | 2023 | Flucelvax Quadrivalent |
| Cranial Technologies, INC | $21.07 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $14.34 | 2023 | Rotateq, Gardasil 9, M-M-R II |
| Aytu Biopharma, INC. | $13.99 | 2024 | Karbinal |
| Genentech USA, INC. | $8.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cierra Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.